GE’s Vivid E9 cardiac ultrasound was on display at the
Healthymagination launch event in Washington, D.C., to illustrate the
types of leaps in quality that can potentially infuse healthymagination
products going forward. It’s built for 4-D, which allows a doctor to see
movement in addition to 3-D views.
เทคโนโลยี ไร้สายกับการนำมาใช้ในทางการแพทย์ Eric Topol (The Scripps Translational Science Institute) ในงาน TEDMED 2009
The future of medicine is wireless
A couple of weeks ago, the (then interim, now full-fledged) president and CEO of CardioNet, Randy Thurman, declared that the company is leading what we believe is a revolution in healthcare – wireless medicine. . . .
In summary, the convergence of healthcare and information technology is resulting in one of the most important trends for the next twenty years – wireless medicine – and CardioNet is uniquely positioned to capitalize on this unprecedented opportunity over the long term.
(These statements were made in the context of fourth quarter and year-end results–the company reported 65% revenue growth in 2008.)
CardioNet is a medical technology company that currently specializes in the remote diagnosis and monitoring of cardiac arrhythmias (an abnormality in the rate or rhythm of the heartbeat). Its Mobile Cardiac Outpatient Telemetry (MCOT), a portable wireless monitoring device, is designed to keep track of a person’s heartbeat 24/7 over an extended period of time as he or she goes about daily life.
Marketed as a service rather than as a product, the MCOT must be prescribed by a physician. The patient wears three chest leads attached to a small sensor that transmits data to the monitor. The monitor analyzes each heartbeat, and when it detects arrhythmias, it automatically sends the data to the CardioNet monitoring center; results are then communicated to the prescribing doctor. When the study period is over, the patient returns the MCOT device to CardioNet.
This years GE Healthcare IN Cell Image competition winners were announced at the High Content Analysis (HCA) Conference in San Francisco, USA, last week. Each of the three regional winners, from Asia, Europe and North America, has won a trip to New York City in March 2010 to see their images shown on NBCs high-definition TV screen in Times Square.
Your doctor has recommended that you undergo a balloon angioplasty with a stent implant. But what does that actually mean?
The heart is located in the center of the chest. It’s job is to keep blood continually circulating throughout the body.
The blood vessels that supply the body with oxygen-rich blood are called arteries.The arteries that supplies blood to the heart muscle itself are called coronary arteries.Sometimes, these blood vessels can narrow or become blocked by plaque deposits, restricting normal blood flow.
In simple terms, a balloon angioplasty with stent insertion is a procedure used to increase the amount of blood flowing through the coronary artery.
During a balloon angioplasty, a heart specialist will insert a thin tube into an artery in your arm or leg and gently guide it towards the problem area in your heart.
Once the tube is in place, a small balloon is briefly inflated in order to widen the narrowed artery.
A short length of mesh tubing called a stent is then inserted into the newly widened artery.During and after the procedure, your doctor will take x-rays in order to monitor your progress.
Aethlon Medical is the developer of the Hemopurifier®,
A first-in-class medical device to treat infectious disease. The Hemopurifier® addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier® are being conducted with researchers at the Government of India’s National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier® in a 24-treatment human study and has received approval to continue further human studies at The Fortis Hospital in India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier® as a broad-spectrum treatment countermeasure against category “A” bioterror threats. Additional information on Aethlon Medical and its Hemopurifier® technology can be accessed at www.aethlonmedical.com.
Apple presented the blueprint for iPhone OS 3.0, the next version of their advanced mobile platform. They showed some really cool new features for the iPhone and iPod Touch, but particularly interesting to me was their enthusiasm about medicine and medical devices.